Replies to post #222474 on Biotech Values

[Zoltarak]

Is this really relevant to ADXS, other than validation osmosis via the competitive landscape growing?

[DewDiligence]

EDGE claims to have evaluated 150 “strategic options” before settling on the reverse merger with PDS.

[hdwrsft]

Competition in the HPV space.

How fast and efficient will is their management team?

How well-studied, well-thought, and effective is their approach?

Will they have 4 CEOs in 10 years?

Will they experience FDA holds?

Will they go through a massive R/S?

.
.
.
.
etc.

etc.



Questions abound.

[DewDiligence]

EDGE +27% — someone likes the reverse-merger plan.

[DewDiligence]

Preliminary proxy for EDGE-PDS reverse merger—no date yet for shareholder votes:

https://www.sec.gov/Archives/edgar/data/1472091/000114036118045551/s002568x1_s4.htm

[DewDiligence]

EDGE begins trading as PDSB pursuant to previously-announced reverse merger:

https://www.globenewswire.com/news-release/2019/03/18/1756135/0/en/PDS-Biotechnology-Completes-Merger-with-Edge-Therapeutics.html